Physician profile
Rajeev Grover
NPI 1952363830
$5,230.93
in general payments reported to CMS, 2019-2025
32 companies · $900 in 2025
The $900 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $341 · 2021: $789 · 2022: $829 · 2023: $885 · 2024: $726 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $727.51 | 2019-2025 | |
| Amgen INC. | $584.86 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $563.61 | 2021-2025 | Verquvo |
| Pfizer INC. | $498.44 | 2019-2025 | |
| Boston Scientific Corporation | $494.50 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Amarin Pharma, INC. | $371.35 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.82 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $308.35 | 2019-2023 | Xarelto |
| Lundbeck LLC | $217.28 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $148.19 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $144.93 | 2020-2025 | Farxiga |
| Edwards Lifesciences Corporation | $114.63 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $104.02 | 2019-2025 | Cardiomems |
| Esperion Therapeutics, INC. | $83.79 | 2022-2024 | Nexletol |
| Medicure Pharma INC. | $69.24 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $65.21 | 2024 | Evkeeza, Praluent |
| Agepha Pharma Fz LLC | $45.48 | 2024 | Lodoco |
| Novo Nordisk INC | $45.40 | 2025 | Wegovy |
| Gilead Sciences, INC. | $28.75 | 2019 | |
| Impulse Dynamics (USA) INC. | $26.99 | 2023 | Optimizer |
| Medtronic, INC. | $22.32 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.64 | 2021 | |
| Avinger INC. | $20.92 | 2021 | |
| Abiomed | $20.59 | 2022 | |
| Heartflow, INC. | $20.00 | 2022 | |
| Inspire Medical Systems, INC. | $19.95 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $19.14 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $17.93 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $16.75 | 2025 | |
| Coala Life INC | $15.05 | 2021 | |
| Cook Medical LLC | $13.96 | 2023 | Zilver Ptx |
| Medicomp INC | $11.33 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.